Real Money authors - Jim Collins

Jim Collins

Jim Collins is the Founding Partner of Portfolio Guru. Collins researches small stocks in his newsletter, MicroCap Guru, and uses income-investing principles to manage money for individuals on a fee-only, separately-managed account basis.

Previously, Collins spent 10 years as an equity analyst in New York and London covering the automotive sector for Lehman Brothers, Donaldson, Lufkin & Jenrette and UBS. He holds an A.B. in Economics and History from Duke University and has completed the academic requirements for the CFA designation. 

Email Jim Collins

Recent Articles By The Author

Watch Tesla and Peloton as They Face Potential Product Liability Issues

The actual hit to reputational damage is much more difficult to quantify.

There Is No Shortage of Kevin Bacon-ing in This Market

The worst example? Netflix. Competition has ended the Golden Years for this streamer.

GE Isn't a Value Play and Has No Earnings Momentum - Buy Some Puts

The company is in a secular downtrend fundamentally, but the stock has risen with the market in this wild ride over the past 12 months.

The Lesson of Bernie Madoff, Investing and the Markets

Knowledge is power and knowledge is the best protection against any type of fraud especially Madoff's insidious brand of affinity fraud.

Stocks Are Crypto

The issue is when the data conflict with the prevailing narrative. We are in such a position now.

I'm Buying Arcturus Therapeutics Stock and Here's the Reason Why

My COVID vaccine eligibility actually began about a week before my symptoms began.

If You Want to Win Big, Think Small, Really Small

As I step into my role as 'Future Man,' I'm looking for undervalued stocks among the sea of supercharged tech names.

Want a Better World? Invest in These 3 Innovative Companies

Remember always that smaller companies require bigger due diligence.

Here's Why I'm Avoiding AstraZeneca Stock

The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.

The FOMC Is Oblivious to Actual Facts

The removal of the SLR exemption is seen as contractionary.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight